IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04400994 |
Recruitment Status :
Recruiting
First Posted : May 26, 2020
Last Update Posted : October 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Pemphigus is a rare acquired autoimmune disease in which immunoglobulin G (IgG) antibodies target desmosomal proteins to produce intraepithelial, and mucocutaneous blisters. It is potentially fatal and the average mortality of pemphigus vulgaris (PV) was 75% before the introduction of corticosteroids in the early 1950s.
Traditionally, treatment of pemphigus included high dose systemic corticosteroids with or without adjuvant immunosuppressants. However; the prolonged use of high dose steroids carries significant side effects. A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases and can potentially induce long-term complete remission and lower risks infectious complications.
In this study, investigators will evaluate the efficacy and safety of early use of rituximab with or without IVIG in patients with moderate to severe pemphigus using protocols that were similar to those previously published, investigators will also aim to measure the impact of health care economics and in doing so, assess the cost and benefits of both treatment arms.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pemphigus | Drug: Rituximab Other: IVIg | Phase 2 |
Pemphigus is a rare acquired autoimmune disease in which immunoglobulin G (IgG) antibodies target desmosomal proteins to produce intraepithelial, and mucocutaneous blisters. It is potentially fatal and the average mortality of pemphigus vulgaris (PV) was 75% before the introduction of corticosteroids in the early 1950s.
Traditionally, treatment of pemphigus included high dose systemic corticosteroids with or without adjuvant immunosuppressants. However; the prolonged use of high dose steroids carries significant side effects. A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Furthermore, early use of rituximab was associated with associated with better clinical outcomes. Moreover, combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases and can potentially induce long-term complete remission and lower risks infectious complications.
Cost effectiveness is an important issue and while combination of IVIG and rituximab has been advocated, the cost of such treatment is substantial and whether it poses any benefit over rituximab alone, or with other more conventional immunosuppressive agents, has not been established. Both treatment approaches have been previously published in high impact journals.
In this study, investigators aim to evaluate the efficacy and safety of early use of rituximab with or without IVIG in patients with moderate to severe pemphigus using protocols that were similar to those previously published. Apart from complete remission and adverse effects, investigators will also aim to measure the impact of health care economics and in doing so, assess the cost and benefits of both treatment arms.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus |
Actual Study Start Date : | June 20, 2020 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2024 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Rituximab only
|
Drug: Rituximab
Rituximab would be given intravenously.
Other Name: MabThera |
Experimental: Rituximab and IVIG
|
Drug: Rituximab
Rituximab would be given intravenously.
Other Name: MabThera Other: IVIg IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg: 0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min & beyond: 180ml/hour Other Name: Privigen |
- relapse-free complete remission [ Time Frame: From baseline up to 208 weeks ]Percentage of participants who achieve relapse-free complete remission
- Time to protocol defined disease flare [ Time Frame: From baseline up to 208 weeks ]Time to protocol defined disease flare
- Duration of complete remission [ Time Frame: From baseline up to 208 weeks ]Duration of complete remission, evaluated by the PDAI activity score
- Number of protocol defined disease flares [ Time Frame: From baseline up to 208 weeks ]Number of protocol defined disease flares
- Time to initial complete remission [ Time Frame: From baseline up to 208 weeks ]Time to initial complete remission, evaluated by the PDAI activity score
- Change in health-related quality of life: Dermatology Life Quality Index (DLQI) Score [ Time Frame: Baseline, Week 4, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192 ]
Change in health-related quality of life as measured by the Dermatology Life Quality Index (DLQI) Score.
The DLQI is calculated by summing the score of each question resulting in maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
- Occurrence of severe treatment adverse events [ Time Frame: Baseline, week 4, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 ]Safety endpoints: Occurrence of treatment adverse events, serious adverse events (grade 3 or 4) based on common terminology criteria for adverse events (CTCAE). Death from any cause. Adverse events leading to discontinuation, vital signs, and laboratory tests
- Blood DSG 1 and 3 levels [ Time Frame: Baseline week 0, week 4, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192 ]Blood DSG 1 and 3 levels
- Blood lymphocyte level (CBC) [ Time Frame: Baseline week 0, week 4, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192 ]Blood lymphocyte level (CBC)
- Blood CD19/20 mean B cell counts percentage [ Time Frame: Week 0, week 4, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192 ]Blood CD19/20 mean B cell counts percentage
- Number of rescue therapy given [ Time Frame: Baseline up to Week 208 ]Number of rescue therapy given

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent obtained from patient
- Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
- Newly or recently diagnosed (less than 18 months) diagnosed pemphigus vulgaris or pemphigus foliaceus based on clinical features; histological features of acantholysis via skin or mucosal biopsy; and intercellular staining pattern of indirect immunofluorescence or serological detection of DSG 1 or DSG 3 by enzyme-linked immunosorbent assay (ELISA)
- Moderate to severe active disease, as defined by overall PDAI >= 15 or skin involvement BSA>= 5%. 9 [Annex 1]
- Receiving standard-of-care oral prednisolone up to 1.5 mg/kg/day
- Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception.
- Ability to comply with study protocol as deemed by investigator's assessment
Exclusion criteria:
- Age <18 or >70
- Pregnant women or nursing mother
- Already diagnosed pemphigus patients diagnosed > 18 months
- Non-consenting patients, or patient who cannot be followed up regularly
- Patient with history of serious allergy or anaphylactic reaction to monoclonal antibody treatment
- Severe heart failure (NYHA Class III or IV)
- Unstable angina or myocardiac infarction within last 3 months or post-infarction heart failure
- Anaemia (haemoglobin <10g/dL), Neutropenia (<1000/mm3), Lymphopenia (<900/mm3), thrombocytopenia (<100,000/mm3)
- Renal insufficiency eGFR <60
- Liver insufficiency of ALT/ALT > 2 times normal limit range
- Positive test results for hepatitis C (HCV) serology at screening *Patients who are HepBs Ag positive, or HepBs Ag negative and anti-HepBc Ab - positive: Patients who are HepBs Ag positive - will be started on entecavir 0.5mg daily, and will be referred to a gastroenterologist for further follow up.
Patients who are HepBs Ag negative, and HBc Ab positive, with detectable HepB DNA levels - will be started on entecavir 0.5mg daily, and will be referred to a gastroenterologist for further follow up.
Patients who are HepBs Ag negative, HBc Ab positive, with no detectable HepB DNA levels - will be started on entecavir 0.5mg daily, and will be continued on entecavir for at least 18 months after completion of last dose of rituximab.
- Blood test positive for HIV
- Signs of active infection on CXR
- Positive interferon gamma release assay Quantiferon or T.Spot TB test: must be treated with at least 4 weeks post initiation of isoniazid or other TB therapy
- Inherited or acquired severe immunodeficiency
- History of malignancy
- Patient with active severe infection (excluding fungal infections of the nail), which has required antibiotic treatment within 2 week prior to study enrolment
- Infection requiring hospitalisation or intravenous antibiotic treatment within the last 8 weeks prior to enrolment
- Past history of osteomyelitis, or fasciitis, septic arthritis within the last one year
- Patients with drug induced pemphigus. A thorough medication history will be taken to rule out drug induced pemphigus including D-penicillamine, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and cephalosporins
- Evidence of any new or uncontrolled concomitant disease that in the investigators' judgement would preclude the patients participation
- Patients with history of allergy or adverse events to IVIG or rituximab treatment10
- Treatment with intravenous immunoglobulins, plasmaphoresis within the last 8 weeks prior to randomization
- Previous treatment with rituximab or any monoclonal antibody inducing profound lymphopenia
- Treatment with live or attenuated vaccine within the last 28 days prior to randomization

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04400994
Contact: Tze Lei Judy Sham, MCoun | +85222556489 | js83213@hku.hk |
Hong Kong | |
Department of Medicine | Recruiting |
Central, Hong Kong | |
Contact: Judy Sham, MCoun +852 22556489 js83213@hku.hk |
Principal Investigator: | Sze Man Wong, MBBS | The University of Hong Kong |
Documents provided by Dr. Sze-Man Wong, The University of Hong Kong:
Responsible Party: | Dr. Sze-Man Wong, Honorary Clinical Assistant Professor, The University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT04400994 |
Other Study ID Numbers: |
UW19-671 |
First Posted: | May 26, 2020 Key Record Dates |
Last Update Posted: | October 21, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Pemphigus intravenous immunoglobulins rituximab |
Pemphigus Skin Diseases, Vesiculobullous Skin Diseases Autoimmune Diseases Immune System Diseases Rituximab |
Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |